Related references
Note: Only part of the references are listed.Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations
Chin Meng Khoo et al.
DIABETES OBESITY & METABOLISM (2021)
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia
Qiuhe Ji et al.
DIABETES OBESITY & METABOLISM (2021)
Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial
Kenya Kusunose et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
Atsushi Tanaka et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
Atsushi Tanaka et al.
ESC HEART FAILURE (2020)
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial
Jesper Jensen et al.
AMERICAN HEART JOURNAL (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?
Atsushi Tanaka et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial
Remo H. M. Furtado et al.
CIRCULATION (2019)
Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
Akira Sezai et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction The DEFINE-HF Trial
Michael E. Nassif et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
W. Timothy Garvey et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
N-terminal pro-brain natriuretic peptide and associated factors in the general working population: a baseline survey of the Uranosaki cohort study
Atsushi Tanaka et al.
SCIENTIFIC REPORTS (2017)
Short term variation in NTproBNP after lifestyle intervention in severe obesity
Debora Fedele et al.
PLOS ONE (2017)
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Bart Staels
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES CARE (2017)
Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
Wataru Ogawa et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial
Atsushi Tanaka et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials
Soichi Sakai et al.
CLINICAL THERAPEUTICS (2016)
Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin
Mitsuyoshi Takahara et al.
ENDOCRINE JOURNAL (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Higher Natriuretic Peptide Levels Associate With a Favorable Adipose Tissue Distribution Profile
Ian J. Neeland et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Share Paper
